Astrocytoma, IDH-mutant, grade 2
MONDO:0956994An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.
2845 clinical trials for this condition and its sub-types, 18 tagged with Astrocytoma, IDH-mutant, grade 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Glowing dye could help surgeons spot hidden brain cancer
Disease control Not yet recruitingThis phase 2 trial tests a single dose of FG001, a fluorescent dye, in 76 adults with newly diagnosed high-grade glioma. The dye is given before surgery and glows under a special light, helping surgeons tell tumor from healthy tissue during removal. The study checks how well the …
Phase 2 • Sponsor: FluoGuide A/S • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC